MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...
AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...
Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...
In September, AstraZeneca's subsidiary MedImmune gained approval for a live H1N1 Flumist vaccine. Further afield, Beijing-based Sinovac Biotech also received approval for an H1N1 vaccine from the ...
This article highlights several inspiring men and women working across academia and industry who are breaking barriers and ...
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...
Following a 20-year career as a commissioned officer in the United States Army, including the last six years as chairman of the Department of Immunology at the Walter Reed Army Institute of Research, ...
Nov. 11, 2024 — Why is the expansion of our Universe accelerating? Twenty-five years after its discovery, this phenomenon remains one of the greatest scientific mysteries. Solving it involves ...
The move comes just before a Biden administration deadline for Israel to deliver more aid to the enclave or risk a cutoff of military supplies. By Hiba Yazbek A day after the prime minister of ...
Background Because inactivated trivalent influenza vaccines (TIVs) contain 1 influenza B strain, whereas 2 lineages may co-circulate, B lineage mismatch is frequent. We assessed an inactivated ...
A trader works at the New York Stock Exchange (NYSE), after Republican presidential nominee Donald Trump won the election, in New York City, U.S., November 6, 2024. REUTERS/Andrew Kelly/File Photo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback